

Efficacy of traditional herbal formulas on human immunity

C. CINGI¹, N. BAYAR MULUK², A. TEZOL³, İ. ÇUKUROVA⁴

¹Department of Otorhinolaryngology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey

²Department of Otorhinolaryngology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey

³Demiroglu Bilim University, Vocational School of Health Services, Istanbul, Turkey

⁴Department of Otorhinolaryngology, Head and Neck Surgery, University of Health Sciences, Izmir Faculty of Medicine, Izmir, Turkey

Abstract. – In the present study, we reviewed the efficacy of traditional herbal formulas on human immunity. A literature survey was performed in PubMed, UpToDate, Proquest Central Databases of Kırıkkale University, Google and Google Scholar databases from the internet. Search key words were “immune”, “immune system”, “herbal”, “*Pelargonium Sidoi-des*”, “*Echinacea Purpurea*”, “*Sambucus Nigra*”, “Beta Glucan”, “Vitamin C”, “Zinc”. The immune system is a natural self-defense mechanism made up of cells that assist the body in distinguishing between self and non-self-molecules. All immune system components must be regularly modified in order to keep the body defenses up against the ever-evolving microbes that are constantly looking for new ways to attack the host. A Chinese herbal formulation is a combination of several herbs. The practitioner begins with one or two major substances that are intended to treat the ailment. The reproducibility of the efficacy of herbal medicines is dependent on the consistency of the quality of each unique raw herb. *Pelargonium Sidoi-des*, *Echinacea Purpurea*, *Sambucus Nigra*, Beta Glucan, Vitamin C, and Zinc are some herbal treatments utilized for their benefits on human immunity. Herbal remedies are undoubtedly valuable in boosting impaired immune function, particularly where damage has occurred due to malnutrition, chronic disease or previous infections. At present, however, an invincible immune system remains firmly in the realm of fantasy.

Key Words:

Immunity, Herbal remedies, *Pelargonium Sidoi-des*, *Echinacea Purpurea*, *Sambucus Nigra*, Beta Glucan, Vitamin C, Zinc.

Introduction

Herbal therapy, acupuncture, massage, and food therapy are all forms of traditional Chinese medicine (TCM). These procedures originated in China and have been used as a component of mainstream medical care in East Asia for centuries. TCM is also emerging as a complementary and alternative medicine (CAM) in Western healthcare¹.

Asthma, atopic dermatitis (AD), and food allergies have all seen dramatic increases in frequency in developed nations over the past few decades. In children, atopic diseases pose a serious threat to public health. Asthma and Alzheimer’s disease are typically treated with conventional drugs like glucocorticoids¹. The success of these treatments is not high in every patient, especially in the young ones. Furthermore, only emergency measures can alleviate the symptoms of a food allergy attack; there is currently no cure. Because of these and other concerns, many patients and their families are turning to CAM therapies¹.

Methods

A literature survey was performed in PubMed, UpToDate, Proquest Central databases of Kırıkkale University and Google and Google Scholar databases from the internet. Search key words are “immune”, “immune system”, “herbal”, “*Pelargonium Sidoi-des*”, “*Echinacea Purpurea*”, “*Sambucus Nigra*”, “Beta Glucan”, “Vitamin C”, “Zinc”.

The Immune System: an Overview

The immune system is a natural self-defense mechanism made up of cells that assist the body in distinguishing between self- and non-self-molecules. Different immune cell pathways assist the body discriminate its own healthy cells from disease-causing organisms such as bacteria, viruses, fungus, parasites, malignant cells, and many more².

All immune system components must be regularly modified in order to keep the body's defenses up against the ever-evolving microbes that are constantly looking for new ways to attack the host. This constantly changing system occasionally reacts against the body's own cells, misidentifying them as foreign, resulting in the death of healthy tissue and the development of autoimmune illnesses and malignancies.

The immune system has several stages of resistance against invading microorganisms. It is made up of physical barriers, innate immunity systems, and adaptive immunity processes. The physical barrier can be mechanical, chemical, or biological, and it can be found at several locations throughout the body, including the skin, secretions in the respiratory system, and flora in the gastrointestinal or genitourinary tract. Within the body, cells with innate and adaptive immunity can be found in a variety of locations, including the blood, lymphatic system (lymph, lymphoid nodules, and lymphoid organs), epithelium, and connective tissues³.

Antigens

Molecules that are identified and activate immune system cells are called antigens. Both individual cellular components (proteins, polysaccharides, or nucleoproteins), and entire cells (tumor cells, or organisms containing genetic material, such as bacteria, viruses, fungi, parasites), or agents carrying nucleic acids or lipids, fall under this category².

There are two ways in which the adaptive immune system can respond to antigen: cellular or humoral. Lymphocytes play a crucial role in the cellular response, while plasma cells produce antibodies in the humoral response. The immune system recognizes specific regions of an antigen called epitopes, and these regions dictate whether the cellular or humoral immune response is mounted against the antigen. A linear amino acid sequence or an antigenic tertiary structure are both examples of epitopes².

Immunoglobulin

Immunoglobulins (Igs), which are sometimes referred to as “antibodies”, are glycoprotein molecules made by B lymphocytes and plasma cells in response to an immunogen or following detection of certain epitopes on the antigen. Antibodies target individual antigens through specific binding. Humoral immunity relies heavily on Ig. The pre-B lymphocyte is the progenitor of all B-lymphocytes and the first cell in the body to make Ig. Daily Ig production by an adult individual is about 2-3 grams².

Antibodies are proteins that can be found in a variety of different locations in the body, including on the surface of lymphocytes as a component of the cell membrane protein, in the bloodstream, or as a gland secretion. The Ig molecule is a polypeptide heterodimer made up of four identical chains: two light chains and two heavy chains linked together *via* disulfide bonds¹.

The Ig family of proteins includes not only antibodies, but also the five isotypes (G, A, M, E, and D) and the subclasses G and A within each isotype. The properties of the antibody's Ig heavy chain serve as a dividing line between the groups. There are V (variable) regions and C (constant) regions in every chain. The antibody binding portion of the molecule to the various antigens consists of the variable region, which varies greatly amongst antibody molecules and consists of around 110 amino acids. Neutrophils, eosinophils, macrophages, dendritic cells, B cells, and NK cells all have Fc receptors that the constant area at the carboxyl-terminal end of the heavy chain, called the Fc region, binds to. The Fc region also plays a role in complement activation¹.

When antibodies bind to their target antigens, the antigens agglutinate and precipitate, rendering themselves ineffective. Covering the antigen's surface with the Fc region of the antibody stimulates the destruction of antigen by cells including macrophages, neutrophils, and eosinophils; this process is known as “opsonization”¹.

Strong Ties

For the Ig classes G, A, M, E, and D, the corresponding heavy chains are denoted by corresponding Greek letters (i.e., γ , α , μ , ϵ , δ). There are four distinct forms of human IgG, designated by the numbers 1, 2, 3, and 4. IgG1 has C1 as its heavy chain, for instance. There are just three CH domains in the constant (C) region of IgG, IgA, and IgD. The C sections of IgM and IgE have 4 CH domains¹ each.

κ and λ light chains can be distinguished by their C-terminal regions. Chromosome 2 encodes for κ , while chromosome 22 does the same for λ . It is impossible for an Ig molecule to have both the κ or λ (60% and 40%). It is impossible for a single B lymphocyte to generate both the κ or λ chains¹.

Regions that Vary

Antibody variety is due to complementarity determining regions (CDRs) of around 10 amino acids, which are located in the variable sections VL and VH and form the antigen-binding sites. Each V region has three complementary variable regions (CDRs), with CDR3 being the most variable and often making the most extensive contact with the antigen¹.

Continual Spaces

Continual Spaces the Ig molecule's C-termini are where CH and CL are found. Only CH binds to Fc receptors and complement to mediate effector activities⁴.

Immune System Cells

Lymphocytes

Lymphocytes can be broken down even further into T cells, B cells, and NK cells. Lymphocyte subsets T and B can only recognize a certain antigen. The receptors found on the surface of each cell give rise to functional differences in their generation and maturation. The B-lymphocytes and natural killer cells both originate in the bone marrow before dispersing to other lymphoid tissues and organs. However, after leaving the bone marrow, T lymphocytes travel to the thymus gland, where they undergo a second round of selective maturation.

Lymphoid tissue contains these cells as well as many others that constantly circulate throughout the body. T cells predominate in the thymus, followed by the blood, the lymph nodes, and finally the spleen, while B lymphocytes predominate in the bone marrow, followed by the spleen, the lymph nodes, and finally the blood. The thymus gland does not contain any B lymphocytes.

When activated, B cells multiply rapidly and secrete antibodies that target the triggering antigen. In some cases, antigen is first delivered to T cells, which subsequently secrete cytokines that excite B lymphocytes. It causes the body to react by making antibodies to fight off the antigen. In addition, during repeated exposure, some B lymphocytes are transformed into memory cells that generate a fast response to the same antigen².

However, T cells can only recognize antigens presented to them coupled to the major histocompatibility complex (MHC), and they too are triggered by receptors on their surface. There are two types of T lymphocytes, the cytotoxic and the helper T cells. T cells that are able to bind to MHC class II molecules are known as helper T cells or CD4+ T cells. When activated, they release a plethora of cytokines which induce the differentiation of B cells into plasma cells, that in turn promotes the manufacture of more antibodies².

The inflammatory response against the given antigen is heavily influenced by cytotoxic T cells and macrophages. CD8+ T cells, also known as MHC Class I restricted T cells, are the cytotoxic T cells. The first way they kill cells is by latching to them and releasing proteins, called perforins, into the cells, which poke holes in the target cell membranes and cause the cells to lyse. Second, they cause apoptosis, which is a form of planned cell death².

Innate immune system cells

In the same way that B and T lymphocytes contain antigen-recognizing receptors on their surface, natural killer cells have them too. They initiate a direct, asymptomatic assault on aberrant or foreign cells, such as cancer and virus-infected cells².

Cells that display antigens

B lymphocytes, macrophages, and dendritic cells (also known as Langerhans cells in the mucosa and epidermis) are all examples of antigen-presenting cells. Helper T cells (CD4+) are presented with peptides bound to class II major histocompatibility complex (MHC) molecules on the surface of these cells.

How Does the Immune System Work?

The antigen presenting cell and major histocompatibility complex pathways

Human leukocyte antigens (HLA) are a subset of major histocompatibility complex (MHC) molecules that are encoded on the MHC locus².

Serological tests were used to detect the presence of MHC molecules at the outset. HLA-A, -B, and -C were the initial MHC molecules discovered. The mixed lymphocyte response assay² was used to determine the presence of HLA-DR, DQ, and DP.

The following are characteristics shared by MHC molecules²:

- One binding site exists on each MHC molecule.
- Cell membranes are where MHC molecules are anchored.
- MHC Class I and II restricted interactions with T lymphocytes necessitate physical touch.
- Co-dominant expression of MHC molecules.
- Cell surfaces express parental MHC molecules

Transmission of antigens for MHC class I

- The endoplasmic reticulum is still the safe haven for newly generated MHC class I polypeptides.
- The proteasome degrades organisms that reach the cytoplasm into antigenic peptides. The proteasome is a multi-subunit proteinase, and transporter associated with antigen processing (TAP) proteins bring antigenic peptides to the endoplasmic reticulum to be processed. Newly generated MHC class I polypeptides are primed with antigenic peptides. The antigenic peptide and MHC class I are taken to the cell surface.
- Antigenic peptide² is necessary for stable MHC class I expression.

The processing of MHC class II antigens

Phagosomes in the cytosol collect and store antigens taken in from the extracellular environment *via* Fc or complement receptors. Phagosomes combine with lysosomes to form a single structure. The bacterium is digested into antigenic peptides² in the resultant phagolysosome.

Cytokines

These include soluble protein molecules (such as IFN-, IL-4, TGF-beta, IL-13, IL-5), which are released by a wide variety of cells in the body (not just immune system cells like lymphocytes, macrophages, or leukocytes)².

To stimulate the immune system, these cytokines have a role in the control of a wide variety of other processes, including growth, development, and the mediation of the inflammatory response. When cytokines have an effect on the cells from which they were secreted, this is called an autocrine effect; when they have an effect on neighboring cells, this is called a paracrine effect; and when they are secreted into the circulation and have an effect on a target organ far from their secreting cells, this is called an endocrine effect².

Immunity's Physical Defenses

Some examples of such physical obstacles are as follows²:

- Skin
- Nails

Barriers in the mucosa

- Fluids produced by the lungs, stomach, and urine systems
- Cilia in the nose

Natural defenses

The components of innate immunity include antimicrobial peptides, pattern recognition receptors, cells, complement components, and a variety of cytokines. It is the first line of defense, but it does not make any long-term memories of the antigens that attacked you.

Innate immunity

T lymphocytes are mostly involved in the cellular response while B lymphocytes are primarily involved in the humoral response during adaptive immunity. After being activated, T lymphocytes secrete a plethora of cytokines that instruct macrophages and other cells to eliminate the presenting antigen. Antigens are destroyed when T cells secrete cytokines that induce B lymphocytes to make antibodies against them. Memory T cells and memory B cells are formed by the immune system following the initial exposure in adaptive immunity, allowing for a more rapid and targeted immune response during repeated encounters with the same pathogen or antigen².

Immunoglobulin production by B cells, which originate in bone marrow and mature there. Linear epitopes, key ligands, markers, and connections (Fc receptors, CD19, CD20, CD21, and MHC II) are all things they can identify.

T lymphocytes are matured B lymphocytes that have their origins in bone marrow. The epitopes they detect are conformational.

There are three possible subtypes of T lymphocytes: CD4⁺ helper T cells, CD8⁺ cytotoxic T cells, and Tregs.

T cells can be further subdivided into effector T lymphocytes and memory T lymphocytes after activation. A second stimulus, or co-stimulation, is needed for activation. Antigen-presenting cells are cells in which the costimulatory chemicals can be found. Their receptors can be found on T cells. Without costimulation, the T lymphocyte response would not occur. An energized (or non-responsive) T cell is one that detects the antigen but does not receive the costimulatory signal.

Inducing negative modulation of the immune response² is one possible effect of costimulators.

Herbal Remedies for Immune Function

TCM treats the whole person, not just the symptoms or the affected organ. Rather, it also emphasizes homeostasis of organ systems, interactions with the environment, and the yin-yang balance (two opposed, but complimentary forces) of the body and mind⁵. There is no direct equivalent in Western medicine for the ideas and terms of traditional Chinese medicine¹.

Every patient receives individualized care. A Chinese herbal formulation, for instance, is a combination of numerous herbs. To treat an ailment, the doctor first uses one or two primary substances. The specific yin-yang conditions of the patient determine which additional substances are included as a catalyst to increase the efficacy of the other components or as an antidote to counteract the negative effects of the other ingredients. As a result, the formulation employed to treat a given condition differs from patient to patient and even within a single patient according to their evolving requirements¹.

Randomized clinical trials have not been conducted on TCM. For instance, sham acupuncture is notoriously tricky to carry off. Herbal formulations are not always standardized in terms of their contents, and even when they are, the quality and pharmacologic activity of the different herbs within the formulation can vary.

To fill up some of the blanks in our understanding of CAM, the National Institutes of Health's National Center for Complementary and Integrative Health (NCCIH) funds both clinical and basic research. To further improve the quality of Chinese herbal medicine, the National Committee of Acupuncture and Oriental Medicine also offers a diploma in Chinese Herbology.

TCM relies heavily on the use of Chinese herbal remedies, which are widely given in China both on their own and in tandem with Western treatment. In the United States, the Food and Drug Administration (FDA) classifies Chinese herbs as dietary supplements. Therefore, there is no requirement for proof of efficacy, safety, or quality, and no obligation to disclose post-marketing adverse events¹.

The FDA recommendations⁶ for the study of botanical medicine products, such as complicated formulae containing multiple plants, with an emphasis on efficacy, safety, and consistency. That is why it makes sense to look into traditional Chinese medicine supplements as potential new plant medicines. The Chemical, Manufacturing, and Control (CMC) Data requirement for new

botanical drugs⁶ is one of the main variations between the standards for researching synthetic and botanical medications set by the US Food and Drug Administration. Raw herb, extract, and finished product quality and safety information are all required for botanical medicines¹.

According to TCM, allergic sickness develops when the balance between the body's many organs and their environments and diets is disturbed, specifically concerning the lungs, skin, and digestive tract. There is much evidence^{7,8} in TCM literature linking asthma, allergic rhinitis, and AD. Even though they have not been extensively researched^{7,8}, numerous widely used formulations exist for these conditions.

High-performance liquid chromatography (HPLC) fingerprinting of the molecular components is used to standardize the quality, potency, and consistency of formulations. Liquid chromatography combined with mass spectrometry¹ is also used to identify chemical markers.

The reproducibility of herbal therapy efficacy depends on the uniformity of the raw herbs used. According to the Pharmacopoeia of the People's Republic of China⁷, factors that affect quality include originality, geographic location, harvest time, preparation procedures, and storage. The reliability and high quality of the final product can be guaranteed to some extent by adhering to standard manufacturing technique. The limits of harmful microorganisms and pesticides are determined, and heavy metal contamination is evaluated, during the product's safety testing phase. Biologic analysis, such as asthma and food allergy *in vitro* and *in vivo* models, may also be used to guarantee safety and efficacy before clinical application in humans. Product quality control for antiasthma herbal medicine intervention (ASHMI) and food allergy herbal formula-2 (FAHF-2)^{1,9-11} has been successful thanks to this combination strategy.

Pelargonium Sidoides

***Pelargonium Sidoides'* Influence on Human Immunity**

The Zulu and Basuto people of South Africa traditionally used African geranium (*Pelargonium sidoides*). It has been suggested that *pelargonium* can help reduce cold and bronchitis symptoms in adults¹²⁻¹⁴. A randomized controlled study published in 2007¹⁵ verified the effects of *pelargonium* in relieving cold symptoms. More studies

are needed to evaluate its efficacy in avoiding Upper Respiratory Tract Infections (URTIs) and in treating influenza-like illness (ILI) across a variety of population subsets. The product has a high safety profile, with only mild allergic reactions and stomach distress reported by users (Zucol™, Abkit, Inc., NY, USA).

The herbal treatment EPs®7630, also known as “Kaloba®” and derived from the plant *Pelargonium sidoides* DC (The standard abbreviation for botanist Augustin Pyramus de Candolle) (*Geraniaceae*), is useful for treating acute bronchitis¹⁶. (*Geraniaceae*) is one of the few current herbal treatments for respiratory infections that has some indication of efficacy. For almost a century, it has been a standard treatment for both diarrhea and tuberculosis in South Africa^{16,17}. He was so confident in its efficacy that he began selling it for tuberculosis therapy in England in 1904, and the reports of tuberculosis (TB) patients’ treated with this remedy^{17,18} quickly spread throughout France and Switzerland. Stevens concealed the plant’s true identity until the 1970s, when it was finally recognized. Since 1991^{16,19}, “Umckaloabo” has been sold throughout Europe to treat bronchitis.

Possible effects of *Pelargonium sidoides* can be explained by plausible processes. EPs® 7630, an extract from the root, exhibits low antibacterial activity²⁰ but increases macrophage activity^{21,22} and decreases group A *streptococci* binding to human epithelial cells^{23,24}. It is effective against many respiratory viruses^{25,26} and inhibits viral infection of human broncho-epithelial cells by decreasing expression of cell membrane docking proteins and increasing expression of host defense proteins²⁷. Antitussive effects have been observed in animal models using mice and guinea pigs^{16,28}.

Human Immunology Clinical Trials Involving *Pelargonium Sidoides*

Although the overall quality of the evidence was judged low²⁹, *Pelargonium sidoides* root extract may be beneficial at treating symptoms of acute bronchitis in both adults and children. All symptoms, cough, and sputum production improved, although results were mixed across three small randomized controlled trials of acute bronchitis in adults²⁹. By day 5³⁰, there had been a significant difference in the bronchitis severity score (BSS)³⁰. The liquid formulation had the potential to be more beneficial than the pills. Regardless of dosage form, *Pelargonium sidoides* reduced symptoms. Although liquid formulations of *Pelargonium sidoides* may be more effective,

it is unclear if they are more widely available than the tablet form. Some doubt exists concerning the relative acceptability of tablet and liquid forms due to the lack of direct comparative data¹⁶.

The UK’s National Institute for Health and Care Excellence (NICE)³¹ recommends *Pelargonium* as a “self-care treatment” for those who want to try it; it has “limited evidence of some benefit for the relief of cough symptoms”. a high-quality independent clinical trial¹⁶ of *Pelargonium sidoides* root extract is warranted.

Otamaxivir® drops with its content (20 mg) of African geranium (*Pelargonium sidoides*), exhibits immunomodulatory, antiviral, antibacterial, and anti-inflammatory effects, while vitamin C (18 mg) contributes to immune defense by supporting various cellular functions of both the natural and acquired immune system. For adults and adolescents aged 11 and above, the suggested dosage is 30 drops (3 × 1.5 ml) three times a day. For children aged 4-10 years, 30 drops (2 × 1.5 ml) twice a day³².

Echinacea Purpurea

Echinacea purpurea products prevent or treat URTI in adults^{13,32}. Taking *E. purpurea* as a preventative measure has been shown^{13,33} to reduce the risk of catching a cold by 58% and shorten its duration by 1.4 days (both statistically significant). In 2006, the *echinacea*’s effectiveness in treating URTIs was reviewed³⁴. Additional thorough trials are indicated to be needed, even if *echinacea* was reported³³ that to be more effective than placebo as a therapy for URTIs. *Echinacea* may help prevent pediatric colds when taken during cold and flu season, according to a large randomized controlled trial³⁵; however, *echinacea* does not appear to diminish the length or intensity of symptoms when used to treat colds in children^{13,36}.

Direct antiviral activity³⁷ has been observed *in vitro* against the influenza virus and the induction of pro-inflammatory cytokines by *echinacea*. The therapeutic significance of this finding in the prevention or treatment of influenza-like illness (ILI) requires further investigation. The quality of *echinacea* supplements sold in the US varies widely. The *Echinacea Madaus* (Madaus GmbH, Köln, Germany) utilized in the majority of the successful experiments is made from the *E. purpurea* species’ aerial parts.

Otamaximun capsules with their content of *Echinacea purpurea* extract (150 mg), alleviate symptoms associated with the common cold and

influenza infections, support the immune system, and enhance overall resistance. Beta-glucan (100 mg), derived from yeast, acts as an immune system activator by stimulating white blood cells, which are responsible for the initial defense of the immune system. Zinc (5 mg) plays a role in the normal development and function of natural immune cells, while vitamin C (60 mg) supports immunity and exhibits antioxidant effects. It is recommended to take it twice a day with meals³⁸.

European Black Elderberry (*Sambucus Nigra*)

The common cold and upper respiratory infection (URI) are commonly treated with *Sambucus Nigra* (European black elderberry) juice, also known as the extract Sambucol® (PharmaCare US, San Diego, CA). Elderberry has been shown^{13,39} to bind to the influenza H1N1 virus *in vitro*, preventing infection. Black elderberry extract (1-4 teaspoons daily for 3-5 days for adults) has been shown⁴⁰⁻⁴² to reduce the severity and duration of flu symptoms, as well as increase immunity to the virus. However, before elderberry is routinely recommended for preventing or treating ILI⁴³, more research is needed to confirm these effects in more diverse North American populations (including children). There is no evidence that elderberry extracts can be used to treat or prevent URTI. Although allergic responses have been reported¹³, elderberry is typically well tolerated.

Otaimuzinc pastille, with its content of Elderberry extract, helps to alleviate symptoms of flu and the common cold while supporting the immune system. Zinc plays a role in the normal development and function of natural immune cells, while vitamin C supports immunity and provides antioxidant effects. Otaimuzinc, in the form of lozenges, is easy to use and can be carried with you at any time. It is flavored with natural flower honey for a delightful taste. The recommended dosage is 4 pastilles per day for individuals aged 11 and above⁴⁴.

Rhizome of Ginger

Ginger (*Zingiber officinale*) is a perennial plant that can get as tall as four feet in ideal conditions^{45,46}. Its summer flowers are a yellowish green and its thin, glossy, brilliant green leaves are rarely seen. The rhizome is the edible and therapeutic portion of the plant. Common terminology for identifying commercial ginger varieties includes their place of origin. This herb is native to the

tropical regions of Southeast Asia, India, Africa, and the West Indies, but it can be grown anywhere with adequate soil and sunlight⁴⁵.

Ginger has been used as a medicine for quite some time. It is one of the most well-known Chinese and Japanese medical herbs, and it is typically used for headaches, nausea, and stomach disorders, as well as colds⁴⁷. “Spicy” and “hot,” ginger is said to “warm the body and treat cold extremities, improve weak and tardy pulses, address pale complexions, and strengthen the body after blood loss⁴⁸”.

Both fresh ginger and dry powdered ginger are utilized in Indian food and Ayurvedic medicine⁴⁹. Ginger’s virya, or potency, according to Ayurvedic practitioners, is “hot.” Ginger is believed to balance the doshas (the three organizing principles providing homeostasis in Ayurvedic medicine), alleviate the symptoms of colds and other viral infections, improve digestion, stimulate appetite, and reduce arthritis. To combat malaria and yellow fever, ginger has been utilized in Nigeria and other African nations. Treatment of urinary tract infections⁵⁰ has included its use in the West Indies.

Although the exact method by which ginger exerts its antiemetic effects remains uncertain, some⁵¹⁻⁵³ have hypothesized that it may have an effect on the digestive system. Several components of ginger inhibit serotonin type 3 receptors, suggesting a central nervous system involvement; however, this has not been convincingly demonstrated. *In vitro* studies^{54,55} have shown that ginger has anti-inflammatory properties, possibly by blocking the cyclooxygenase and lipoxygenase pathways in the metabolism of arachidonic acid.

Although ginger’s active ingredients are not yet fully understood, gingerols and shogaols have been isolated from studies⁵⁶ using lipophilic rhizome extracts. The vast majority of studies^{52,57,58} have found that ginger improves GI motility. Platelet aggregation *in vitro* was dose-dependently reduced by aqueous extracts of the fresh rhizome⁵⁴. Platelet prostaglandin endoperoxides and thromboxane B2 production were both considerably suppressed by the extract. However, after two weeks of daily ingestion, neither 15 g of raw ginger rhizome nor 40 g of cooked rhizome reduced platelet cyclooxygenase activity⁵⁹ in 18 healthy volunteers. Eight healthy volunteers were given a single 2-g dose of the dried rhizome, and the results⁶⁰ showed no clinically significant differences in bleeding time, platelet count, or platelet functionality compared to placebo.

It was not until a 1982 investigation by Mowrey and Clayson⁶¹ that ginger was subjected to a clinical trial in the West. In a study⁴⁵ including 36 male and female college students who reported a high vulnerability to motion sickness, the effects of 940 milligrams of powdered ginger rhizome were compared to those of 100 milligrams of dimenhydrinate or placebo. When given 20-25 minutes before testing in a motorized spinning chair, ginger was more effective than dimenhydrinate and placebo for preventing motion sickness.

To avoid nausea and vomiting, ingesting 500-1,000 milligrams of powdered dry rhizome an hour before exposure has been found to be effective⁶²⁻⁶⁴. This is similar to 2-4 grams of fresh or candied rhizome, or roughly 1 inch of the material. The administration of 500-1,000 milligrams (mg) of powdered rhizome daily has been studied⁵⁵ for the treatment of arthritic conditions like rheumatoid and osteoarthritis.

In humans, ginger has never been linked to any negative reactions. For seven days at 2.5 g/kg/day, there were no negative effects in animal tests evaluating acute toxicity, while doses of 3-3.5 g/kg/day killed 10-30% of the animals⁵⁵. Single 2-gram dosages of dried ginger rhizome did not have a clinically significant effect on platelet aggregation in healthy subjects^{45,60}.

Vitamins and Minerals to Boost the Immune System

Beta Glucan

Glucans belong to a class of biologically active natural compounds and development interest as a result of their potential uses as immunostimulant⁶⁵.

β -1,3-Glucans (henceforth referred to as glucan) are naturally occurring compounds that have been shown⁶⁶ to have profound effects on human health. They are examples of pathogen-associated molecular patterns (PAMPs; for a review, see Zipfel and Robatzek⁶⁶), which are highly conserved structures shared by many different types of pathogens. In the 1940s, Shear et al⁶⁷ described a polysaccharide compound derived from the seaweed *Serratia marcescens*, which triggered tumor necrosis; this discovery marked the beginning of the use of polysaccharides as immunomodulators. Rathgeb and Sylvén⁶⁸ made the first attempt to determine the structure of this so-called Shear's polysaccharide. They concluded that the polysaccharide was made up of glucose

residues based on methylation analyses and periodate oxidation. Polysaccharides obtained from more benign species like yeasts, mushrooms, or even bananas⁶⁹ have been the focus of immunomodulatory research because bacterial extracts and separated products can be harmful. In the course of immune system development, multicellular creatures picked up the ability to identify certain molecules as foreign, prompting a variety of defensive responses. Thus, from invertebrates to humans, every species encodes the ability to identify glucans^{65,70,71}.

Bohn and BeMiller⁷² published a review of the literature on the subject of structure-functional activity relationships in respect to the biological activities of β -(1,3)-glucans. They emphasized the significance of the β -(1,3)-glucan backbone, but they also pointed out many glaring discrepancies in the published data on the impact of molecular weight, water solubility, the degree of 6-*O*-substitution by glucopyranosyl units, global chain conformation, and intermolecular associations on antitumor activity and the mechanisms involved by these glucans. However, there was no definitive determination. Writers interested in learning more about this topic might check out Novak and Vetvicka⁷³.

Studies⁷⁴⁻⁷⁶ confirmed that glucan strongly stimulates the immune systems of many different animals and humans alike (including worms, bees, shrimp, fish, chicken, rats, rabbits, guinea pigs, sheep, goat, pigs, cows, primates, and more). As a result of this research, we know that glucans are one of the rare immunostimulants that are functional across the whole evolutionary tree. Glucan has been shown to aid in the defense of plants in a number of experiments^{65,77,78}.

The macrophage is the most important biological target of glucans because of its ability to stimulate cellular immunity. In the initial wave of research, glucan's role in providing immunity from infection was identified. Protective benefits of glucan treatment against *Leishmania major*, *C. albicans*, *T. gondii*, *S. suis*, *P. berghei*, *S. aureus*, *E. coli*, *M. corti*, *T. cruzi*, *E. vermiformis*, *B. anthracis*, and *B. pseudomallei*^{65,79-91}.

Vitamin C (Vitamin 6)

Ascorbic acid (vitamin C) is the most commonly thought nutrient to prevent respiratory viral infections. Prophylactic vitamin C supplementation (200 mg or more daily) does not reduce the incidence of URTI in most adults. However, according to studies¹³, taking vitamin C supple-

ments has been associated to a 50% reduction in the chance of acquiring a cold in a subgroup study of 642 very healthy persons participating in highly physically strenuous activities (marathon runners, skiers, and soldiers on subarctic exercises). Vitamin C has also been found to reduce the duration of cold symptoms by 8 percentage points in adults and 14 percentage points in children.

Deficits in vitamin C has been shown⁹²⁻⁹⁴ to reduce the effectiveness of the immunological response to influenza virus infections in male mice. Vitamin C has moderate *in vitro* antiviral action against influenza virus. Supplemental vitamin C may help to prevent or treat seasonal or atypical influenza, although there are no clinical studies to back this claim¹³.

Vitamin C can cause diarrhea and stomach pain if taken in amounts higher than 3 to 6 grams per day, but otherwise has a tolerability profile not dissimilar from that of placebo. In children and healthy adults subjected to physical stress, vitamin C appears to be most effective as a preventative agent to shorten the duration of URTI symptoms. There is not enough evidence to advocate its usage for prevention or treatment of ILI¹³, and it does not seem to be helpful once symptoms have begun.

Zinc

Zinc, an essential mineral, is crucial for proper immune system function. Many enzymes rely on zinc for their structure, and it also acts as an intracellular signal between immune cells^{13,95}. Zinc regulates the functioning of nearly every type of immune cell, and a lack of it can impair both humoral and cell-mediated immunity, leaving the body more vulnerable to infection.

Pneumonia is more common in people with low zinc levels, and it tends to be more severe. Zinc supplementation has been proven^{96,97} to reduce the prevalence of pneumonia in children in underdeveloped countries. Zinc supplementation reduced the occurrence of acute lower respiratory tract infections in children by about 15%, according to a meta-analysis of studies⁹⁸. More research in healthier populations is needed to determine if zinc supplements are useful in preventing or treating influenza-like diseases.

Zinc supplementation (15 mg daily for 7 months) was not related with a reduction in the prevalence of upper respiratory illnesses⁹⁹ in a 2009 research of healthy Air Force cadets. Children who took a zinc gluconate glycine lozenge (Cold-EEZE[®]), according to open-label

research⁹⁹, experienced a 25% reduction in the duration of cold symptoms. Positive effects of zinc supplementation were found¹⁰⁰⁻¹⁰² in those people who started taking it soon after their symptoms started and who utilized products without citric or tartaric acid. Zinc may not be any more effective than a placebo in treating the common cold, according to a meta-analysis¹⁰³ published between 1996 and 2006. In a more recent randomized controlled trial¹⁰³, zinc supplementation significantly reduced symptom severity but not duration in Turkish children who began supplementation soon after cold symptoms arose. A second recent study used zinc lozenges (13.3 mg of zinc acetate every 2 to 3 hours while awake) or a placebo in a randomized controlled experiment including adults. Both the severity and duration of symptoms decreased in the zinc group, and no serious side effects were reported^{13,104,105}.

Lozenges made from zinc gluconate and glycine are generally well tolerated and safe¹⁰³; however, there are side effects like a metallic taste, nausea, and stomach distress in some users. Lozenges pose a choking hazard and should not be given to children under the age of three. Zinc-containing nasal swabs and sprays have been linked¹⁰⁶ to anosmia (loss of sense of smell) and should be avoided pending the results of more research.

Zinc lozenges and nasal swabs are not the same as homeopathic zinc medicines, which are extremely diluted solutions that are normally very safe¹³.

Although zinc supplementation does not appear to lessen the risk for upper respiratory infections in healthy, well-nourished populations, it nevertheless seems sensible to avoid zinc deficiency. Lozenges have shown inconsistent results in lowering the length and severity of already-present URTIs. Zinc nasal gels and swabs may be safe to use, however lozenges may not be. While homeopathic zinc remedies are risk-free to use, there is no evidence from clinical trials showing that they are effective in preventing or treating URTI or ILI¹³.

We advise against taking zinc due to its dubious advantages and recognized bad effects, especially irreversible anosmia when delivered intranasally, even if zinc formulations may reduce the severity and duration of cold symptoms. There is some evidence from systematic reviews¹⁰⁷⁻¹⁰⁹ that zinc intake is correlated with a shorter duration and milder intensity of cold symptoms. Higher

zinc levels (more than 75 mg daily) were found to shorten the duration of cold symptoms compared to lower doses (less than 25 mg daily) in a systematic review¹⁰⁸. Zinc was found to shorten the time adults experienced symptoms (mean difference -1.65 days, 95% CI -2.5 to -0.8) in a meta-analysis¹⁰⁹; however, there was substantial heterogeneity between trials. Negative side effects, such as nausea and a metallic taste in the mouth, were common in the zinc group across all studies¹⁰⁹.

The FDA issued a public health statement¹¹⁰ warning against the use of Zicam and other zinc-containing intranasal medications due to repeated complaints of irreversible loss of smell. In addition to oral zinc supplements, intranasal zinc gluconate is also available as a homeopathic remedy for the treatment and prevention of the common cold. Hyposmia and anosmia have also been linked¹¹¹ to this formulation. Syrups and lozenges containing zinc sulfate have been demonstrated¹¹² to be more well-tolerated than some tablet forms.

Conclusions

Herbal remedies are undoubtedly valuable in boosting impaired immune function, particularly where damage has occurred due to malnutrition, chronic disease or previous infections. At present, however, an invincible immune^{113,114} system remains firmly in the realm of fantasy. Herbal therapies like Otamaxivir® drops³², Otamaximun capsule³⁸, Otaimuzinc pastille (Otacı, Kurtsan İlaçları, Istanbul, Turkey)⁴⁴, which include these compounds, can be used to support standard medical care for patients with cough.

Conflict of Interest

Author Ayda Senol works in Otacı, Kurtsan İlaçları, Istanbul, Turkey. The other authors declare that they do not have any conflict of interest with this paper.

Funding

No funding was obtained from any companies or organizations for this paper.

Authors' Contribution

Authors equally contributed to planning, literature survey and writing the manuscript.

ORCID ID

Cemal Cingi: 0000-0003-3934-5092

Nuray Bayar Muluk: 0000-0003-3602-9289

Ayda Tezol: 0009-0001-8846-2212

İbrahim Çukurova: 0000-0002-2398-339.

Ethics Approval and Informed Consent

Not applicable.

References

- 1) Wang J. Chinese herbal medicine for the treatment of allergic diseases. In: Sicherer SH, TePas E (Eds). UpToDate. Last updated: Jul 15, 2022.
- 2) Buddiga P. Immune System Anatomy. In: Gest TR (Ed). Medscape. Updated: Nov 22, 2013. Available at: https://emedicine.medscape.com/article/1948753-overview?icd=login_success_email_match_norm (Accessed online on April 27, 2023).
- 3) Sarpe V, Jacob C. Simulating the decentralized processes of the human immune system in a virtual anatomy model. BMC Bioinformatics 2013; 14 Suppl 6: S2.
- 4) Le T, Haymore B, Trujillo VH. ACAAI Review for the Allergy & Immunology Boards 2010.
- 5) www.nccam.nih.gov/health/backgrounds/wholemed.htm (Accessed on February 11, 2010).
- 6) Radix glycyrrhizae. In: WHO monographs on selected medicinal plants, World Health Organization, Geneva 1999. Vol 1, p. 183.
- 7) The State Pharmacopoeia Commission of the People's Republic of China. Pharmacopoeia of the People's Republic of China, 6th ed, People's Medical Publishing House, Beijing 2005.
- 8) Bensky D, Barolet R. Chinese herbal medicine: Formulas and strategies, Eastland Press, Seattle 1990.
- 9) Li XM, Brown L. Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol 2009; 123: 297.
- 10) Kelly-Pieper K, Patil SP, Busse P, Yang N, Sampson H, Li XM, Wisnivesky JP, Kattan M. Safety and tolerability of an antiasthma herbal Formula (ASHMI) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase I study. J Altern Complement Med 2009; 15: 735.
- 11) Zhang T, Srivastava K, Wen MC, Yang N, Cao J, Busse P, Birmingham N, Goldfarb J, Li XM. Pharmacology and immunological actions of a herbal medicine ASHMI on allergic asthma. Phytother Res 2010; 24: 1047.
- 12) Timmer A Günther J, Rücker G, Motschall E, Antes G, Kern WV. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev 2008: CD006323.

- 13) Kemper KH. Complementary and Alternative Medicine Therapies for Cold and Flu Season: What Is the Science? November 03, 2009. https://www.medscape.com/viewarticle/711485_0 (Accessed online on April 27, 2023).
- 14) Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. *Phytomedicine* 2008; 15: 378-385.
- 15) Lizogub VG, Riley DS, Heger M. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. *Explore (NY)* 2007; 3: 573-584.
- 16) Willcox M, Simpson C, Wilding S, Stuart B, Soilemezi D, Whitehead A, Morgan A, Wrixon E, Zhu S, Yao G, Webley F, Yan R, Bostock J, Bell M, Griffiths G, Leydon G, Little P, Butler C, Hay AD, Moore M. Pelargonium sidoides root extract for the treatment of acute cough due to lower respiratory tract infection in adults: a feasibility double-blind, placebo-controlled randomised trial. *BMC Complement Med Ther* 2021; 21: 48.
- 17) Sechehaye A. The treatment of tuberculosis with Umckaloabo (Stevens' cure) London: B. Fraser & Co.; 1929.
- 18) Sechehaye A. The treatment of tuberculous affections with Umckaloabo. London: B. Fraser & Co; 1938.
- 19) Brendler T, van Wyk BE. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). *J Ethnopharmacol* 2008; 119: 420-433.
- 20) Kayser O, Kolodziej H. Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. *Planta Med* 1997; 63: 508-510.
- 21) Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. *Phytotherapy research: PTR* 2001; 15: 122-126.
- 22) Conrad A, Hansmann C, Engels I, Daschner FD, Frank U. Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro. *Phytomedicine* 2007; 14 (Suppl 6): 46-51.
- 23) Conrad A, Jung I, Tioua D, Lallemand C, Carrapatoso F, Engels I, et al. Extract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro. *Phytomedicine* 2007; 14 (Suppl 6): 52-59.
- 24) Janecki A, Conrad A, Engels I, Frank U, Kolodziej H. Evaluation of an aqueous-ethanolic extract from Pelargonium sidoides (EPs(R) 7630) for its activity against group A-streptococci adhesion to human HEp-2 epithelial cells. *J Ethnopharmacol* 2011; 133: 147-152.
- 25) Michaelis M, Doerr HW, Cinatl J Jr. Investigation of the influence of EPs(R) 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. *Phytomedicine* 2011; 18: 384-386.
- 26) Theisen LL, Muller CP. EPs(R) 7630 (Umckaloabo(R)), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. *Antivir Res* 2012; 94: 147-156.
- 27) Roth M, Fang L, Stolz D, Tamm M. Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. *PLoS One* 2019; 14: e0210702.
- 28) Bao Y, Gao Y, Koch E, Pan X, Jin Y, Cui X. Evaluation of pharmacodynamic activities of EPs(R) 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis. *Phytomedicine* 2015; 22: 504-509.
- 29) Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. *Cochrane Database Syst Rev* 2013; 10.
- 30) Matthys H, Kamin W. Positioning of the bronchitis severity score (BSS) for standardised use in clinical studies. *Curr Med Res Opin* 2013; 29: 1383-1390.
- 31) NICE. NICE guideline NG 120. Cough (acute): antimicrobial prescribing: National Institute for Health and Care Excellence; 2019. Available at: <https://www.nice.org.uk/guidance/ng120/chapter/Recommendations>.
- 32) Otacı. Otamaxivir® drops. Kurtsan İlaçları. Available at: <https://otacigidatakviyeleri.com/urunler/otamaxivir/> (Accessed online on June 15, 2023).
- 33) Shah SA, Sander S, White CM, Rinaldi M, Coleman Cl. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. *Lancet Infect Dis* 2007; 7: 473-480.
- 34) Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. *Cochrane Database Syst Rev* 2006: CD000530.
- 35) Weber W, Taylor JA, Stoep AV, Weiss NS, Standish LJ, Calabrese C. Echinacea purpurea for prevention of upper respiratory tract infections in children. *J Altern Complement Med* 2005; 11: 1021-1026.
- 36) Taylor JA, Weber W, Standish L, Quinn H, Goesling J, McGann M, Calabrese C. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. *JAMA* 2003; 290: 2824-2830.
- 37) Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. *Antiviral Res* 2009; 83: 165-170.
- 38) Otacı. Otamaximum capsule. Kurtsan İlaçları. Available at: <https://otacigidatakviyeleri.com/urunler/otamaximum/> (Accessed online on June 15, 2023).

- 39) Roschek B Jr, Fink RC, McMichael MD, Li D, Alberte RS. Elderberry flavonoids bind to and prevent H1N1 infection in vitro. *Phytochemistry* 2009; 70: 1255-1261.
- 40) Zakay-Rones Z, Varsano N, Zlotnik M, Manor O, Regev L, Schlesinger M, Mumcuoglu M. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (*Sambucus nigra* L.) during an outbreak of influenza B Panama. *J Altern Complement Med* 1995; 1: 361-369.
- 41) Barak V, Halperin T, Kalickman I. The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines. *Eur Cytokine Netw* 2001; 12: 290-296.
- 42) Zakay-Rones Z, Thom E, Wollan T, Wadstein J. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. *J Int Med Res* 2004; 32: 132-140.
- 43) Vlachojannis JE, Cameron M, Chrubasik S. A systematic review on the sambuci fructus effect and efficacy profiles. *Phytother Res* 2010; 24: 1-8.
- 44) Otacı. Otaimuzinc pastille. Kurtsan İlaçları. Available at: <https://otacigidatakviyeleri.com/urunler/otaci-otaimuzinc/> (Accessed online on June 15, 2023).
- 45) Grant KL. Alternative Therapies: Ginger. *Am J Health Syst Pharm* 2000; 57. Available at: <https://www.medscape.com/viewarticle/406882> (Accessed online on April 27, 2023).
- 46) Western Garden Book. Menlo Park, CA: Sunset; 1995. Available at: <https://cmc.marmot.org/Record/b11572929> (Accessed online on May 17, 2023).
- 47) Yoshikawa M, Yamaguchi S, Kunimi K, Matsuda H, Okuno Y, Yamahara J, Murakami N. Stomachic principles in ginger. III. An anti-ulcer principle, 6-gingesulfonic acid, and three monoacyldigalactosylglycerols, gingerglycolipids A, B, and C, from *Zingiberis Rhizoma* originating in Taiwan. *Chem Pharm Bull (Tokyo)* 1994; 42: 1226-1230.
- 48) Chang CP, Chang JY, Wang FY, Chang JG. The effect of Chinese medicinal herb *Zingiberis rhizoma* extract on cytokine secretion by human peripheral blood mononuclear cells. *J Ethnopharmacol* 1995; 48: 13-19.
- 49) Sharma H, Clark C. Contemporary Ayurveda. New York: Churchill Livingstone; 1998.
- 50) Bone K. Ginger. *Br J Phytother* 1997; 4: 110-120.
- 51) Phillips S, Hutchinson S, Ruggier R. *Zingiber officinale* does not affect gastric emptying rate: a randomised, placebo-controlled, crossover trial. *Anaesthesia* 1993; 48: 393-395.
- 52) Micklefield GH, Redeker Y, Meister V, Jung O, Greving I, May B. Effects of ginger on gastroduodenal motility. *Int J Clin Pharmacol Ther* 1999; 37: 341-346.
- 53) Lumb AB. Mechanism of antiemetic effect of ginger. *Anaesthesia* 1993; 48: 1118. Letter.
- 54) Srivastava KC. Aqueous extracts of onion, garlic and ginger inhibit platelet aggregation and alter arachidonic acid metabolism. *Biomed Biochim Acta* 1984; 43: S335-346.
- 55) Srivastava KC, Mustafa T. Ginger (*Zingiber officinale*) in rheumatism and musculoskeletal disorders. *Med Hypotheses* 1992; 39: 342-348.
- 56) Bisset NG, ed. Herbal drugs and phytopharmaceuticals: a handbook for practice on a scientific basis. Boca Raton, FL: CRC Press; 1994.
- 57) Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of ginger on motion sickness susceptibility and gastric function. *Pharmacology* 1991; 42: 111-120.
- 58) Sharma JN, Srivastava KC. Suppressive effects of eugenol and ginger oil on arthritic rats. *Pharmacology* 1994; 49: 314-318.
- 59) Janssen PL, Meyboom S, van Staveren WA, de Vegt F, Katan MB. Consumption of ginger (*Zingiber officinale* Roscoe) does not affect ex vivo platelet thromboxane production in humans. *Eur J Clin Nutr* 1996; 50: 772-774.
- 60) Lumb AB. Effect of dried ginger on human platelet function. *Thromb Haemost* 1994; 71: 110-111.
- 61) Mowrey DB, Clayson DE. Motion sickness, ginger, and psychophysics. *Lancet* 1982; 1: 655-657.
- 62) Fetrow CW, Avila JR. Professional's handbook of complementary and alternative medicines. Springhouse, PA: Springhouse, 1999.
- 63) Blumenthal M. The complete German Commission E monographs. Austin, TX: American Botanical Council, 1998.
- 64) Foster S, Tyler VE. Tyler's honest herbal: a sensible guide to the use of herbs and related remedies. 4th ed. New York: Haworth Herbal Press, 1999.
- 65) Vetvicka V, Vannucci L, Sima P, Richter J. Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials. *Molecules* 2019; 24: 1251.
- 66) Zipfel C, Robatzek S. Pathogen-associated molecular pattern-triggered immunity: Veni, vidi...? *Plant Physiol* 2010; 154: 551-554.
- 67) Shear MJ, Turner FC, Perrault A, Shovelton T. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from *Serratia marcescens* (*Bacillus prodigiosus*) culture filtrate. *J Natl Cancer Inst* 1943; 4: 81-97.
- 68) Rathgeb P., Sylven B. Fractionation studies on the tumor-necrotizing agent from *Serratia marcescens* (Shear's polysaccharide). *J Natl Cancer Inst* 1954; 14: 1099-1108.
- 69) Yang J, Tu J, Liu H, Wen L, Jiang Y, Yang B. Identification of an immunostimulatory polysaccharide in banana. *Food Chem* 2019; 277: 46-53.
- 70) Iwanaga S., Lee B.L. Recent advances in the innate immunity of invertebrate animals. *J Biochem Mol Biol* 2005; 38: 128-150.

- 71) Soltanian S, Stuyven E, Cox E, Sorgeloos P, Bossier P. Beta-glucans as immunostimulant in vertebrates and invertebrates. *Crit Rev Microbiol* 2009; 35: 109-138.
- 72) Bohn JA, BeMiller JN. (1→3)-β-D-Glucans as biological response modifiers: A review of structure-functional activity relationships. *Carbohydr Polym* 1995; 28: 3-14.
- 73) Novak M, Vetvicka V. Development of views on β-glucan composition and structure. In: Vetvicka V, Novak M, editors. *Biology and Chemistry of Beta Glucan*. Volume 1. Bentham Science; Sharjah, UAE, 2011, pp. 1-9.
- 74) Vetvicka V, Richter J, Svozil V, Rajnohova Dobiasova L, Kral V. Placebo-driven clinical trials of Transfer Point Glucan #300 in children with chronic respiratory problems: Antibody production. *Am J Immunol* 2013; 9: 43-47.
- 75) Dawood MAO, Eweedah NM, Moustafa EM, Shahin MG. Synbiotic Effects of *Aspergillus oryzae* and β-Glucan on Growth and Oxidative and Immune Responses of Nile Tilapia, *Oreochromis niloticus*. *Probiotics Antimicrob Proteins* 2020; 12: 172-183.
- 76) Mukhopadhyaya A, O'Doherty JV, Sweeney T. A combination of yeast beta-glucan and milk hydrolysate is a suitable alternative to zinc oxide in the race to alleviate post-weaning diarrhoea in piglets. *Sci Rep* 2019; 9: 616.
- 77) Anusuya S., Sathiyabama M. Foliar application of beta-D-glucan nanoparticles to control rhizome rot disease of turmeric. *Int J Biol Macromol* 2015; 72: 1205-1212.
- 78) Menard R, de Ruffray P, Fritig B, Yvin JC, Kauffmann S. Defense and resistance-inducing activities in tobacco of the sulfated beta-1,3 glucan PS3 and its synergistic activities with the unsulfated molecule. *Plant Cell Physiol* 2005; 46: 1964-1972.
- 79) Al Tuwaijri AS, Mahmoud AA, Al Mofleh IA, Al Khuwaitir SA. Effect of glucan on *Leishmania* major infection in BALB/c mice. *J Med Microbiol* 1987; 23: 363-365.
- 80) Cook J.A., Holbrook T.W. Immunogenicity of soluble and particulate antigens from *Leishmania donovani*: Effect of glucan as an adjuvant. *Infect Immun* 1983; 40: 1038-1043.
- 81) Bacon J.S., Farmer V.C. The presence of a predominantly beta(1-6) component in preparations of yeast glucan. *Biochem J* 1968; 110: 34P-35P.
- 82) Bousquet M, Escoula L, Pipy B, Bessieres MH, Chavant L, Seguela JP. Enhancement of resistance of mice *Toxoplasma gondii* by 2 polysaccharides beta 1-3, beta 1-6 (PSAT and Scleroglucan) *Ann Parasitol Hum Comp* 1988; 63: 398-409.
- 83) Dritz SS, Shi J, Kielian TL, Goodband RD, Nelsen JL, Tokach MD, Chengappa MM, Smith JE, Blecha F. Influence of dietary beta-glucan on growth performance, nonspecific immunity, and resistance to *Streptococcus suis* infection in weanling pigs. *J Anim Sci* 1995; 73: 3341-3350.
- 84) Kumar P, Ahmad S. Glucan-induced immunity in mice against *Plasmodium berghei*. *Ann Trop Med Parasitol* 1985; 79: 211-213.
- 85) Liang J, Melican D, Cafro L, Palace G, Fisette L, Armstrong R, Patchen ML. Enhanced clearance of a multiple antibiotic resistant *Staphylococcus aureus* in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. *Int J Immunopharmacol* 1998; 20: 595-614.
- 86) Rasmussen LT, Seljelid R. Dynamics of blood components and peritoneal fluid during treatment of murine *E. coli* sepsis with beta-1,3-D-polyglucose derivatives. *J Cells Scand J Immunol* 1990; 32: 321-331.
- 87) White TR, Thompson RC, Penhale WJ, Chihara G. The effect of lentinan on the resistance of mice to *Mesocostoides corti*. *Parasitol Res* 1988; 74: 563-568.
- 88) Williams DL, Yaeger RG, Pretus HA, Browder IW, McNamee RB, Jones EL. Immunization against *Trypanosoma cruzi*: Adjuvant effect of glucan. *Int J Immunopharmacol* 1989; 11: 403-410.
- 89) Yun C.H., Estrada A., Van Kessel A., Gajadhar A., Redmond M., Laarveld B. Immunomodulatory effects of oat beta-glucan administered intragastrically or parenterally on mice infected with *Eimeria vermiformis*. *Microbiol Immunol* 1998; 42: 457-465.
- 90) Vetvicka V., Terayam K., Mandeville R., Brousseau P., Kournikakis B., Ostroff G. Pilot study: Orally-administered yeast β1,3-glucan prophylactically protects against anthrax infectin and cancer in mice. *JANA* 2002; 5: 1-5.
- 91) Douglas RM, Hemila H, Chalker E, Treacy B. Vitamin C for preventing and treating the common cold. *Cochrane Database Syst Rev* 2007: CD000980.
- 92) Furuya A, Uozaki M, Yamasaki H, Arakawa T, Arita M, Koyama AH. Antiviral effects of ascorbic acid and dehydroascorbic acids in vitro. *Int J Mol Med* 2008; 22: 541-545.
- 93) Jariwalla RJ. Roomi MW, Gangapurkar B, Kalinovskiy T, Niedzwiecki A, Rath M. Suppression of influenza A virus nuclear antigen production and neuraminidase activity by a nutrient mixture containing ascorbic acid, green tea extract and amino acids. *Biofactors* 2007; 31: 1-15.
- 94) Li W, Maeda N, Beck MA. Vitamin C deficiency increases the lung pathology of influenza virus-infected gulo-/- mice. *J Nutr* 2006; 136: 2611-2616.
- 95) Haase H, Rink R. Functional significance of zinc-related signaling pathways in immune cells. *Annu Rev Nutr* 2009; 29: 133-152.
- 96) Meydani SN, Hamer DH. Serum zinc and pneumonia in nursing home elderly. *Am J Clin Nutr* 2007; 86: 1167-1173.

- 97) Natchu UC, Fataki MR, Fawzi WW. Zinc as an adjunct for childhood pneumonia - interpreting early results. *Nutr Rev*. 2008; 66: 398-405.
- 98) Brown KH, Peerson JM, Baker SK, Hess SY. Preventive zinc supplementation among infants, preschoolers, and older prepubertal children. *Food Nutr Bull* 2009; 30: S12-S40.
- 99) Veverka DV, Wilson C, Martinez MA, Wenger R, Tamosuinas A. Use of zinc supplements to reduce upper respiratory infections in United States Air Force Academy cadets. *Complement Ther Clin Pract* 2009; 15: 91-95.
- 100) McElroy BH, Miller SP. Effectiveness of zinc gluconate glycine lozenges (Cold-Eeze) against the common cold in school-aged subjects: a retrospective chart review. *Am J Therapeutics* 2002; 9: 472-475.
- 101) Garland ML, Hagmeyer KO. The role of zinc lozenges in treatment of the common cold. *Ann Pharmacother* 1998; 32: 63-69.
- 102) Caruso TJ, Prober CG, Gwaltney JM Jr. Treatment of naturally acquired common colds with zinc: a structured review. *Clin Infect Dis* 2007; 45: 569-574.
- 103) Kurugol Z, Akilli M, Bayram N, Koturoglu G. The prophylactic and therapeutic effectiveness of zinc sulphate on common cold in children. *Acta Paediatr* 2006; 95: 1175-1181.
- 104) Prasad AS, Beck FW, Bao B, Snell D, Fitzgerald JT. Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. *J Infect Dis* 2008; 197: 795-802.
- 105) Silk R, LeFante C. Safety of zinc gluconate glycine (Cold-Eze) in a geriatric population: randomized, placebo-controlled, double-blind trial. *Am J Ther*. 2005; 12: 612-617.
- 106) Alexander TH, Davidson TM. Intranasal zinc and anosmia: the zinc-induced anosmia syndrome. *Laryngoscope* 2006; 116: 217-220.
- 107) Sexton DJ, McClain MT. The common cold in adults: Treatment and prevention. In: Aronson MD, Hirsch MS (Eds). *UpToDate*. Last updated: Mar 24, 2022.
- 108) Hemilä H. Zinc lozenges may shorten the duration of colds: a systematic review. *Open Respir Med J* 2011; 5: 51.
- 109) Science M, Johnstone J, Roth DE, Guyatt G, Loeb M. Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials. *CMAJ* 2012; 184: E551-561.
- 110) Food and Drug Administration (FDA). Available at: <http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm166931.htm> (Accessed on April 04, 2011).
- 111) Davidson TM, Smith WM. The Bradford Hill criteria and zinc-induced anosmia: a causality analysis. *Arch Otolaryngol Head Neck Surg* 2010; 136: 673.
- 112) Singh M, Das RR. Zinc for the common cold. *Cochrane Database Syst Rev* 2011; CD001364.
- 113) Jackson DJ, Akuthota P, Roufousse F. Eosinophils and eosinophilic immune dysfunction in health and disease. *Eur Respir Rev* 2022; 31: 210150.
- 114) Mancuso G, Midiri A, Gerace E, Biondo C. Role of the innate immune system in host defence against fungal infections. *Eur Rev Med Pharmacol Sci* 2022; 26: 1138-1147.